Response of CO₂ and H₂O fluxes in a mountainous tropical rainforest in equatorial Indonesia to El Niño events

The possible impact of El Niño–Southern Oscillation (ENSO) events on the main components of CO₂ and H₂O fluxes between the tropical rainforest and the atmosphere is investigated. The fluxes were continuously measured in an old-growth mountainous tropical rainforest in Central Sulawesi in Indonesia using the eddy covariance method for the period from January 2004 to June 2008. During this period, two episodes of El Niño and one episode of La Niña were observed. All these ENSO episodes had moderate intensity and were of the central Pacific type. The temporal variability analysis of the main meteorological parameters and components of CO₂ and H₂O exchange showed a high sensitivity of evapotranspiration (ET) and gross primary production (GPP) of the tropical rainforest to meteorological variations caused by both El Niño and La Niña episodes. Incoming solar radiation is the main governing factor that is responsible for ET and GPP variability. Ecosystem respiration (RE) dynamics depend mainly on the air temperature changes and are almost insensitive to ENSO. Changes in precipitation due to moderate ENSO events did not have any notable effect on ET and GPP, mainly because of sufficient soil moisture conditions even in periods of an anomalous reduction in precipitation in the region

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. RESULTS: At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P = 0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P = 0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P = 0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P = 0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P = 0.31). Conclusions: Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. (Funded by Novartis; CANTOS ClinicalTrials.gov number, NCT01327846.

Impression de biomolécules par lithographie douce, applications pour les biopuces, de l échelle micrométrique à nanométrique

L objectif des travaux est de démontrer que la lithographie douce, quelquefois baptisée Micro-Contcat Printing ( CP) , constitue une méthode de dépôt de biomolécules présentant de nombreux avantages pour des applications de type Biopuces. Pour la fabrication de puces à ADN, nous démontrons que le CP est une technique compétitive par rapport au dépôt robotisé de gouttes traditionnellement utilisé. Le coût est inférieur, la densité des puces est augmentée et la qualité et la définition des motifs biomoléculaires sont supérieures. Une étude complète des mécanismes d encrage des timbres élastomères d impression ainsi que des mécanismes de transfert par contact des molécules vers le substrat est présentée. Le rôle prépondérant des fragments de polymère non réticulés présents à la surface des timbres est mis en évidence. Dans un second volet nous étudions la possibilité de générer par la même méthode des puces à biomolécules uniques. Nous montrons comment le CP peut être poussé jusqu à une résolution sub-micrométrique proche de 50 nm. Une voie technologique originale impliquant la lithographie douce est proposée : peigner individuellement en des sites organisés précisément sur la surface des longs brins d ADN pour des études de génétiqueThe main purpose of this research work is the demonstration that soft-lithography, very often called Micro-Contact Printing ( CP) is an efficient patterning technique for arranging biomolecules on a surface in the perspective of biochip applications. For DNA Micro-arrays applications, we demonstrate that CP is a competitive method compared to the conventional spotting technology, commonly used today. The cost of the technology is much lower, the surface density of the chip is drastically increased and the quality and definition of the biopatterns are greatly improved. A systematic study of the inking mechanisms of the elastomeric stamps is provided together with the study and comprehension of transfer mechanisms of molecules from the surface of the stamp to the substrate. The crucial role played by the free fragments of polymers not cross-linked during the polymerisation of the stamp is highlighted. In a second section we investigate the possibility of using CP for generating single biomolecule biochips. We show how this printing technique can be optimized for reaching sub-micrometric scale down to 50 nanometers features. A technological process involving soft-lithography is proposed: combing long DNA molecules on spatially organized and registered positions for genetic applicationsINIST-CNRS (INIST), under shelf-number: RP 17272 / SudocSudocFranceF

Iterative learning control - recent progress and open research questions

BACKGROUND: High accrual to clinical trials enables new treatment strategies to be tested rapidly, accurately and with generalisability. Ethical standards also must be high so that participation is voluntary and informed. However, this can be difficult to achieve in trials with complex designs and in those which are closely embedded in clinical practice. Optimal recruitment requires a balance of both ethical and accrual considerations. In the context of a trial of stratified treatments for children with acute lymphoblastic leukaemia (UKALL2003) we examined how recruitment looked to an observer and how it felt to the parents, to identify how doctors' communication could promote or inhibit optimal recruitment. METHODS: We audio-recorded, transcribed and analysed routine doctor-patient consultations (n = 20) and interviews between researchers and parents (n = 30 parents) across six UK treatment centres. Analysis was informed by the constant comparative method. For consultation transcripts, analysis focussed on how doctors presented the trial. We compared this with analysis of the interview transcripts which focussed on parents' perceptions and understanding of the trial. RESULTS: Parents and doctors discussed the trial in most consultations, even those that did not involve a decision about randomisation. Doctors used language allying them both with the trial and with the parent, indicating that they were both an 'investigator' and a 'clinician'. They presented the trial both as an empirical study with a scientific imperative and also as offering personalisation of treatment for the child. Parents appeared to understand that trial involvement was voluntary, that it was different from routine care and that they could withdraw from the trial at any time. Some were confused about the significance of the MRD test and the personalisation of treatment. CONCLUSIONS: Doctors communicated in ways that generally promoted optimal recruitment, indicating that trials can be embedded into clinical practice. However, parents were unclear about some details of the trial's rationale, suggesting that recruitment to trials with complicated designs, such as those involving stratified treatments, might need enhanced explanation